The Frequency of ANA-positivity and Inflammatory Markers in COVID-19
COVID-19 and ANA-positivity
Abstract views: 135
/ 
PDF downloads: 84
DOI:
https://doi.org/10.5281/zenodo.7562171Keywords:
Antibodies, Antinuclear / immunology, Autoimmunity, COVID-19Abstract
Background: Immune system activation plays an important role in pathogenesis and mortality in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The inflammatory response during the disease is caused by the innate and adaptive immune systems. Anti-nuclear antibody (ANA) positivity rate increases in SARS-CoV-2-positive patients due to adaptive immune system activation. This study aims to investigate the association between ANA-positivity rate and pulmonary symptoms, and inflammatory markers (C-reactive protein [CRP] and fibrinogen).
Material and Methods: One hundred five consecutive patients with the diagnosis of COVID-19 were included in this cross-sectional study. Participants were divided into groups according to the ANA and pulmonary symptom status. Clinical (gender, age) and biochemical (hemogram, liver function tests, kidney function tests, D-Dimer, CRP, and fibrinogen) were compared between the groups and the impact of ANA positivity on pulmonary symptoms development was assessed.
Results: Of the 105 patients, 60 of them had no pulmonary symptoms. The remaining 45 patients had at least one pulmonary symptom. ANA immunofluorescence assay (IFA) positivity rate was 19% (20/105 patients) in the study group. 60% of the ANA-positive patients were positive at 1/160, 30% at 1/320 and 10% at 1/1000 titer. ANA-IFA positivity rate was found higher among patients with pulmonary symptoms; however, the difference was not statistically significant (26.7% vs. 8/60 13.3%, respectively; p=.085). The CRP and fibrinogen levels were (6.9 vs. 3.4, p=.132, and 346.5 vs. 326, p=.183) among ANA positive and negative patients. Twelve (63.2%) patients with ANA-positivity had pulmonary symptoms, and 33 (39.3%) patients with ANA-negativity had pulmonary symptoms (p=0.058).
Conclusions: Although there is no difference between patients with or without pulmonary symptoms, ANA, which may reflect the pathogenetic role of adaptive immune dysregulation, can often be detected in patients with Coronavirus disease 2019.
References
Krishnan A, Hamilton JP, Alqahtani SA, A Woreta T. A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations. Intern Emerg Med. 2021;16(4):815-830. doi:10.1007/s11739-020-02616-5
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet.2020;395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0
Hanna R, Dalvi S, Sălăgean T, Pop ID, Bordea IR, Benedicenti S. Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review. J Inflamm Res. 2021;14:13-56. Published 2021 Jan 7. doi:10.2147/JIR.S282213
Mahase E. Covid-19: Hydrocortisone can be used as alternative to dexamethasone, review finds. BMJ. 2020;370:m3472. Published 2020 Sep 4. doi:10.1136/bmj.m3472
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446. Published 2020 Jun 16. doi:10.3389/fimmu.2020.01446
Zhou Y, Han T, Chen J, et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020;13(6):1077-1086. doi:10.1111/cts.12805
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published correction appears in JAMA. 2021 Mar 16;325(11):1113]. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020;3:100073. doi:10.1016/j.jtauto.2020.100073
Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi:10.1016/ s0065-2776(08)60641-0
Litwin CM, Binder SR. ANA testing in the presence of acute and chronic infections. J Immunoassay Immunochem. 2016;37(5):439-452. doi:10.1080/15”321819.2016.1174136
Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?. Clin Transl Sci. 2021;14(2):502-508. doi:10.1111/cts.12908
Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92(10):1875-1883. doi:10.1002/jmv.26050
Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128-136.e4. doi:10.1016/j. jaci.2020.05.008
Wang G, Wu C, Zhang Q, et al. C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation. Open Forum Infect Dis. 2020;7(5):ofaa153. Published 2020 Apr 29. doi:10.1093/ofid/ofaa153
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [published correction appears in N Engl J Med 1999 Apr 29;340(17):1376]. N Engl J Med. 1999;340(6):448-454. doi:10.1056/NEJM199902113400607
Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020;92(11):2409-2411. doi:10.1002/jmv.26097
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. doi:10.1111/ jth.14768
Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):11161120. doi:10.1515/cclm-2020-0188
Downloads
Published
How to Cite
License
Copyright (c) 2023 Tugba Izci Duran, Melih Pamukcu, Sanem Kayhan, Ismet Battal, Mehmet Derya Demirag
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 